Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822871 · ClinicalTrials.gov registry record · Phase 1
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Cancer Targeted Technology.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03822871: Completed Phase 1 study, sponsored by Cancer Targeted Technology.
NCT03822871 is a Phase 1 study that has completed, run by Cancer Targeted Technology. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03822871, a Phase 1 study, has completed, sponsored by Cancer Targeted Technology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
Interventions
- DRUG 68Ga-PSMA-11
- DRUG CTT1057
- DRUG CTT1403
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2023-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822871
The ClinicalTrials.gov registry entry for NCT03822871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cancer Targeted Technology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 68Ga-PSMA-11 is the first listed.
NCT03822871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03822871 about?
NCT03822871 is a clinical study titled "A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer". The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT03822871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-04-01. Estimated completion is 2023-02-08.
What interventions are being tested in trial NCT03822871?
The interventions under investigation include: 68Ga-PSMA-11 (DRUG), CTT1057 (DRUG), CTT1403 (DRUG).
Who is sponsoring clinical trial NCT03822871?
This trial is sponsored by Cancer Targeted Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.